D
iagnostic testing and surveillance are critical, complementary strategies to combat pathogen outbreaks such as COVID-19. Sequencing-based surveillance helps public health officials track the path of the epidemic, understand transmission routes, determine the rate of viral evolution, and understand if the virus is changing in ways that impact therapeutic effectiveness. As a leader in next-generation sequencing, Illumina is working with practitioners and researchers around the world to provide the vital testing capacity needed for a data-driven response. Three distinguished leaders of Illumina will join SynBioBeta founder John Cumbers for a conversation about sequencing and the novel coronavirus, including:
